On your final point, that simply isn't true. It's simply not true. Vertex understand very well the well-established appraisal mechanisms we have right across the United Kingdom for new medicines: the National Institute for Health and Care Excellence appraisal system that we sign up to, the particular appraisal systems also available in Scotland, and here in Wales through the All Wales Medicines Strategy Group. What they have done, in reaching an agreement with England, which is in the text of Simon Stevens's letter, is they've agreed to provide real-time patient data on a basis where they've agreed a price for access to be made available for every patient for whom the treatment and the condition are indicated, and they will then submit their whole portfolio, with that real-time data, to NICE for appraisal. Now that makes sense, and that was not the proposal that was ever provided here in Wales.

I am clear that we are not responsible in Wales for holding up access to these medicines. The issue is that Vertex need to do what they've committed to do, which is in Simon Stevens's letter. And that is the start and the end of the matter. No family in Wales should be put into a less advantageous position than a family across our border because of an inability to meet the terms of the deal that has been agreed. I look forward to a positive and constructive response from the pharmaceutical company.